DBV Technologies Enters Into Collaboration Agreement With Bionet-Asia And University of Geneva On Whooping Cough Booster Vaccine  
11/26/2013 10:02:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS, BANGKOK, Thailand and GENEVA, Nov. 26, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext Paris:DBV), creator of ViaskinĀ®, announced today that it has entered into a collaboration agreement with BioNet-Asia Co. Ltd and the University of Geneva (UNIGE) to work on a whooping cough (pertussis) booster vaccine. The clinical proof of concept product candidate will combine BioNet's unique recombinant non-toxic Pertussis Toxin (rPT) with DBV's ViaskinĀ® technology, which allows for the epicutaneous delivery of the antigen without any adjuvant.

Help employers find you! Check out all the jobs and post your resume.